Estrella Immunopharma

ESLA

Market cap $33.6M

ESLA Hedge Fund Activity: Q1 2026 in Review

16 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q1 2026, worth a combined $5.49M — up 252% from $1.56M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ESLA positions and 6 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $4.71M. The largest seller was Citadel Advisors, exiting entirely with an estimated $100K sold.

• 16 institutional investors held Estrella Immunopharma (ESLA) as of Q1 2026, up from 15 in Q4 2025.
• Funds reported $5.49M of Estrella Immunopharma stock for Q1 2026, up 252% quarter-over-quarter.
• 8 funds opened new Estrella Immunopharma positions in Q1 2026 and 6 closed out, a net change of +2 holders.
• The largest Estrella Immunopharma buyer in Q1 2026 was Armistice Capital, an estimated $4.71M added.
• The largest Estrella Immunopharma seller in Q1 2026 was Citadel Advisors, an estimated $100K sold.

Based on aggregated 13F filings for Q1 2026.